Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: A single-center experience

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 133-140

  Boehm, Alexandra ^a   Walcherberger, Barbara ^a   Sperr, Wolfgang R ^a   Wöhrer, Stefan ^a   Dieckmann, Karin ^a   Rosenmayr, Agathe ^a   Pernicka, Elisabeth ^a   Fischer, Gottfried ^a   Worel, Nina ^a   Mitterbauer, Gerlinde ^a   Schwarzinger, Ilse ^a   Mitterbauer, M ^a   Haas, Oskar A ^b   Lechner, Klaus ^a   Hinterberger, W ^a   Valent, Peter ^a,c   Greinix, Hildegard T ^a   Rabitsch, Werner ^a   Kalhs, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Allogeneic stem cell transplantation; CML; GVHD; Imatinib

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOSPORIN A; IMATINIB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952799331     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.06.019     Document Type: Article

References (41)

1. Vardiman JW, Pierre R, Thiele J, Imbert M, Brunning RD, Flandrin G. Chronic myelogenous leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lympoid Tissues. Lyon, Fance: IARC Press; 2001 p. 20-26.
2. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40:79-86.
3. Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106:1306-1315.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Druker BJ, Guilhot F, O'Brien SG, et al. IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
6. O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
7. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
8. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
9. Weisberg E, Griffin JD. Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Update. 2003;6:231-238.
10. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.
11. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487-491.
12. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913-923.
13. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol. 2008;142: 361-378.
14. Saussele S, Lauseker M, Gratwohl A, et al. German CML Study Group. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115:1880-1885.
15. Kebriaei P, Detry MA, Giralt S, et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007;110:3456-3462.
16. Crawley C, Szydlo R, Lalancette M, et al. Chronic Leukemia Working Party of the EBMT, Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969-2976.
17. Platzbecker U, Ehninger G, Schmitz N, Bornhäuser M. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases. Ann Hematol. 2003;82:463-468.
18. Tomblyn M, Chiller T, Einsele H, et al. Center for International Blood and Marrow Research. National Marrow Donor program. European Blood and MarrowTransplant Group. American Society of Blood and Marrow Transplantation. Canadian Blood and Marrow Transplant Group. Infectious Diseases Society of America. Society for Healthcare Epidemiology of America. Association of Medical Microbiology and Infectious Disease Canada. Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143-1238.
19. Styczynski J, Reusser P, Einsele H, et al. Second European Conference on Infections in Leukemia. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43:757-770.
20. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550-1561.
21. Cutler C, Antin JH. Chronic graft-versus-host disease. Curr Opin Oncol. 2006;18:126-131.
22. Finke J, Bethge WA, Schmoor C, et al. ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855-864.
23. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006;91:405-408.
24. Fischer GF, Faé I, Petrasek M, Moser S. A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and -DQB 1 alleles. Vox Sang. 1995;69:328-335.
25. Greinix HT, Faé I, Schneider B, et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant. 2005; 35:57-62.
26. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993; 82:691-703.
27. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
28. Winston DJ, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant. 1991;8:7-11.
29. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23: 5675-5687.
30. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729-735.
31. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97:3390-3400.
32. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
33. Sullivan KM, Shulman HM, Storb R, et al. Chronic graftversus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-276.
34. Iscn. An international system for human cytogenetic nomenclature. Cytogenet Cell Genet. 1981;31:5-23.
35. Mitterbauer G, Födinger M, Scherrer R, et al. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia. Br J Haematol. 1995;89:937-941. Erratum in: Br J Haematol. 1995;90:492.
36. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Soc. 1999;94:496-509.
37. Baccarani M, Saglio G, Goldman J, et al. European Leukemia-Net. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
38. Rodriguez J, Cortes J, Talpaz M, et al. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000;6:147-152.
39. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
40. Deininger M, Schleuning M, Greinix H, et al. European Blood and Marrow Transplantation Group. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91:452-459.
41. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109:1782-1789.